PL2338487T3 - Terapia skojarzona z inhibitorami PARP - Google Patents

Terapia skojarzona z inhibitorami PARP

Info

Publication number
PL2338487T3
PL2338487T3 PL11157696T PL11157696T PL2338487T3 PL 2338487 T3 PL2338487 T3 PL 2338487T3 PL 11157696 T PL11157696 T PL 11157696T PL 11157696 T PL11157696 T PL 11157696T PL 2338487 T3 PL2338487 T3 PL 2338487T3
Authority
PL
Poland
Prior art keywords
combination therapy
parp inhibitors
parp
inhibitors
therapy
Prior art date
Application number
PL11157696T
Other languages
English (en)
Inventor
Wolfgang Wernet
Thomas D Penning
Vincent L Giranda
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of PL2338487T3 publication Critical patent/PL2338487T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11157696T 2006-01-17 2007-01-17 Terapia skojarzona z inhibitorami PARP PL2338487T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75944506P 2006-01-17 2006-01-17
US80411206P 2006-06-07 2006-06-07
US85004206P 2006-10-06 2006-10-06
US82926106P 2006-10-12 2006-10-12
US86751806P 2006-11-28 2006-11-28
EP07716699A EP1976515A2 (en) 2006-01-17 2007-01-17 Combination therapy with parp inhibitors
EP11157696.3A EP2338487B1 (en) 2006-01-17 2007-01-17 Combination therapy with PARP inhibitors

Publications (1)

Publication Number Publication Date
PL2338487T3 true PL2338487T3 (pl) 2014-03-31

Family

ID=38141258

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11157696T PL2338487T3 (pl) 2006-01-17 2007-01-17 Terapia skojarzona z inhibitorami PARP

Country Status (14)

Country Link
US (4) US20070265324A1 (pl)
EP (3) EP2329818A1 (pl)
JP (4) JP5289060B2 (pl)
CN (1) CN101370497B (pl)
CA (1) CA2635691C (pl)
DK (1) DK2338487T3 (pl)
ES (1) ES2437132T3 (pl)
HR (1) HRP20131180T1 (pl)
ME (1) ME02121B (pl)
PL (1) PL2338487T3 (pl)
PT (1) PT2338487E (pl)
RS (1) RS53082B (pl)
SI (1) SI2338487T1 (pl)
WO (1) WO2007084532A2 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59911249D1 (de) 1998-11-03 2005-01-13 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
WO2006110683A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
US20070015814A1 (en) * 2005-06-10 2007-01-18 Ernest Kun Parp Modulators and Treatment of Cancer
NZ587586A (en) 2005-07-18 2012-04-27 Bipar Sciences Inc Treatment of cancer
ES2378692T3 (es) * 2005-09-29 2012-04-17 Abbott Laboratories Las 1H-benzimidazol-4-carboxamidas sustituidas con fenilo en la posición 2 son potentes inhibidores de PARP
EP1966157B1 (en) * 2005-11-15 2010-03-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
ATE553104T1 (de) * 2006-05-02 2012-04-15 Abbott Lab Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
WO2008030891A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
NZ586125A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
US20090275608A1 (en) * 2008-02-04 2009-11-05 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
CN103052390A (zh) * 2010-08-03 2013-04-17 内尔维阿诺医学科学有限公司 包含parp-1抑制剂和抗肿瘤剂的治疗组合
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
NZ616227A (en) 2011-04-11 2016-01-29 Abb Vie Inc Parp inhibitors for the treatment of cipn
EP2849750A1 (en) 2012-05-15 2015-03-25 AbbVie Inc. Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
CN104230896A (zh) * 2013-06-17 2014-12-24 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
MX2016007433A (es) 2013-12-10 2016-09-13 Abbvie Inc Veliparib en combinacion con carboplatino para el tratamiento de cancer de mama triple negativo.
KR102501566B1 (ko) * 2014-01-14 2023-02-17 넥타르 테라퓨틱스 병용 기반 치료 방법
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2017031442A1 (en) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
JP2018528185A (ja) 2015-08-21 2018-09-27 イプセン バイオファーム リミティド リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法
CN105712937B (zh) * 2016-02-28 2019-02-22 河北宁格生物医药科技有限公司 一种治疗转移性肿瘤的化合物及其用途
KR20190077441A (ko) 2016-11-02 2019-07-03 입센 바이오팜 리미티드 리포솜성 이리노테칸, 옥살리플라틴, 5-플루오로우라실 (및 류코보린)을 포함하는 조합 요법을 사용하는 위암 치료
GB201709076D0 (en) * 2017-06-07 2017-07-19 Inst Of Cancer Research: Royal Cancer Hospital Parp inhibitors for use in methods of treating cancer
MA51524A (fr) * 2018-01-05 2020-11-11 Cybrexa 1 Inc Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques
JP7372253B2 (ja) 2018-04-05 2023-10-31 ノビガ・リサーチ・エービー 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ
CN109232540A (zh) * 2018-06-15 2019-01-18 深圳市坤健创新药物研究院 一种取代苯并咪唑衍生物及应用
CN108997320A (zh) * 2018-08-30 2018-12-14 深圳市坤健创新药物研究院 一种含氟取代苯并咪唑衍生物及应用
CA3139180A1 (en) * 2019-03-27 2020-10-01 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
CN114302744B (zh) 2019-07-10 2025-08-26 赛博克萨3公司 作为治疗剂的微管靶向剂的肽缀合物
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
CN114053415B (zh) * 2020-07-30 2024-06-18 江苏天士力帝益药业有限公司 Tsl-1502复方药物组合
US12293220B2 (en) 2022-04-21 2025-05-06 Dell Products L.P. Context-driven framework to migrate the applications and its dependencies by analyzing the relationships
CA3172480A1 (en) 2022-04-27 2023-10-27 Susanne KOSSATZ Combination treatment of small-cell lung cancer
CN118615452A (zh) * 2023-03-07 2024-09-10 中国科学院分子细胞科学卓越创新中心 Dna损伤药物联合化疗
US12292781B2 (en) 2023-04-21 2025-05-06 Dell Products L.P. Method and system for managing power consumption for devices

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510154A (ja) * 1995-08-02 1999-09-07 ニューキャッスル ユニバーシティ ベンチャーズ リミテッド ベンズイミダゾール化合物
ATE207359T1 (de) * 1995-08-28 2001-11-15 Schering Corp Kombinationstherapie für fortgeschrittenes krebsstadium mit temozolomid und cisplatin
NZ335012A (en) * 1997-07-02 2000-01-28 Atochem North America Elf paint or varnish base containing acrylic fluoropolymer resins
RU2001117757A (ru) * 1998-11-27 2004-02-27 БАСФ Акциенгезельшафт (DE) Замещенные бензимидазолы и их применение в качестве ингибиторов поли(аденозиндифосфатрибоза)полимеразы
RS50031B (sr) * 1999-01-11 2008-11-28 Agouron Pharmaceuticals Inc., Triciklični inhibitori poli(adp-riboza)polimeraza
AU780892B2 (en) * 1999-03-30 2005-04-21 Merck Sharp & Dohme Corp. Improved cancer treatment with temozolomide
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
WO2001021615A1 (fr) * 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
AU2003229953A1 (en) * 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2004087713A1 (en) * 2003-03-31 2004-10-14 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
AU2004242947B2 (en) * 2003-05-28 2010-04-29 Eisai Inc. Compounds, methods and pharmaceutical compositions for inhibiting PARP
WO2006052976A2 (en) * 2004-11-09 2006-05-18 Schering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient’s mgmt level
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US20070015814A1 (en) * 2005-06-10 2007-01-18 Ernest Kun Parp Modulators and Treatment of Cancer
WO2006137510A1 (ja) * 2005-06-24 2006-12-28 Ono Pharmaceutical Co., Ltd. 脳血管障害時における出血低減剤

Also Published As

Publication number Publication date
CN101370497B (zh) 2010-11-17
RS53082B (sr) 2014-06-30
EP1976515A2 (en) 2008-10-08
CA2635691C (en) 2013-10-29
WO2007084532A2 (en) 2007-07-26
JP2013136605A (ja) 2013-07-11
WO2007084532A3 (en) 2007-09-07
DK2338487T3 (da) 2013-12-09
CA2635691A1 (en) 2007-07-26
US20120045524A1 (en) 2012-02-23
EP2338487A1 (en) 2011-06-29
JP2017160216A (ja) 2017-09-14
SI2338487T1 (sl) 2014-01-31
HRP20131180T1 (hr) 2014-01-31
CN101370497A (zh) 2009-02-18
EP2329818A1 (en) 2011-06-08
ME02121B (me) 2014-06-30
US20110151023A1 (en) 2011-06-23
JP6147799B2 (ja) 2017-06-14
JP2015187114A (ja) 2015-10-29
JP5289060B2 (ja) 2013-09-11
ES2437132T3 (es) 2014-01-09
US20110152336A1 (en) 2011-06-23
PT2338487E (pt) 2013-12-16
US20070265324A1 (en) 2007-11-15
EP2338487B1 (en) 2013-09-11
JP2009523801A (ja) 2009-06-25

Similar Documents

Publication Publication Date Title
SI2338487T1 (sl) Kombinacijska terapija z inhibitorji PARP
IL196559A0 (en) Combination therapy
GB0609492D0 (en) Therapeutic agents
GB2436010B (en) Therapy device
ZA200904860B (en) Combination therapy with angiogenesis inhibitors
EP2032168A4 (en) COMBINED THERAPY BASED ON CAPECITABINE
EP2035005A4 (en) THERAPY BASED ON CYTOKINE INHIBITORS
GB0608928D0 (en) Therapeutic agents
IL196556A0 (en) Combination therapy
GB0601962D0 (en) Therapeutic agents
IL199992A0 (en) Combination therapy
HRP20130041T8 (en) Therapeutic agents
EP2054061A4 (en) COMBINATION THERAPY
GB0723747D0 (en) Therapeutic agents
GB0616214D0 (en) Therapeutic Agents
ZA200902203B (en) Combination therapy
IL198026A0 (en) Sequential combination therapy
GB0611152D0 (en) Therapeutic agents
EP2211863A4 (en) COMBINATION THERAPY
GB0620818D0 (en) Therapeutic agents
GB0700284D0 (en) Combination therapy
GB0620059D0 (en) Therapeutic agents
GB2441007B (en) Auricular therapy
GB0609676D0 (en) Therapeutic agents
GB0606660D0 (en) Targeted Therapy